Target family: Bombesin receptors (type: gpcr)
Target: BB<sub>1</sub> receptor

Ligand: [125I][Tyr4]bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [125I]BH-NMB (human, mouse, rat) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Rhodei-litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.34 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: Rhodei-litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.34 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: Rhodei-litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.99 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: Rhodei-litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: ranatensin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: ranatensin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.89 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: ranatensin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.89 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.33 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.69 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.33 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: [Phe13]bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: [Phe13]bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [Phe13]bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: PD 176252 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: PD 168368 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: PD 168368 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: PD 165929 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.199999809265137 pKd
Reference (Journal): PD 165929- the first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist.
Published in: Bioorg Med Chem Lett

Ligand: neuromedin B (1-30) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: neuromedin B (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.
Published in: Pharmacol Rev

Ligand: neuromedin B (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Insights into bombesin receptors and ligands: Highlighting recent advances.
Published in: Peptides

Ligand: MK-5046 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist.
Published in: J Pharmacol Exp Ther

Ligand: MK-5046 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): Comparative Pharmacology of Bombesin Receptor Subtype-3, Nonpeptide Agonist MK-5046, a Universal Peptide Agonist, and Peptide Antagonist Bantag-1 for Human Bombesin Receptors.
Published in: Pharmacol Exp Therap

Ligand: litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.15 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.15 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [Leu8]-phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [Leu8]-phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50

Ligand: [Leu8]-phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: [Leu8]-phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.84 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: kuwanon H (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.19 pKi
Reference (Journal): Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry.
Published in: Biochem Biophys Res Commun

Ligand: JMV641 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.820000171661377 pIC50
Reference (Journal): Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor.
Published in: J Biol Chem

Ligand: JMV594 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor.
Published in: J Biol Chem

Ligand: gastrin releasing peptide(14-27) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: gastrin releasing peptide(14-27) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.64 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: [D-Phe6, Leu13, Cpa14,ψ13-14]bombesin-(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [D-Phe6,β-Ala11,Phe13,Nle14]bombesin-(6-14) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: [D-Phe6,β-Ala11,Phe13,Nle14]bombesin-(6-14) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: [D-Phe6,β-Ala11,Phe13,Nle14]bombesin-(6-14) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: dNal-cyc(Cys-Tyr-dTrp-Orn-Val)-Nal-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: D-Nal,Cys,Tyr,D-Trp,Orn,Val,Cys,Nal-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
Published in: Mol Pharmacol

Ligand: D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: bantag-1 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Comparative Pharmacology of Bombesin Receptor Subtype-3, Nonpeptide Agonist MK-5046, a Universal Peptide Agonist, and Peptide Antagonist Bantag-1 for Human Bombesin Receptors.
Published in: Pharmacol Exp Therap

Ligand: bantag-1 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity.
Published in: Cell Metab

Ligand: neuromedin B (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides